Hawley C Almstedt1, Makenzie M Cook2, Lily F Bramble2, Deepa V Dabir3, Joseph W LaBrie4. 1. Human Performance Laboratory, Department of Health and Human Sciences, Loyola Marymount University, 1 LMU Drive MS 8888, Los Angeles, CA, 90045, USA. Hawley.almstedt@lmu.edu. 2. Human Performance Laboratory, Department of Health and Human Sciences, Loyola Marymount University, 1 LMU Drive MS 8888, Los Angeles, CA, 90045, USA. 3. Department of Biology, Loyola Marymount University, 1 LMU Drive MS 8888, Los Angeles, CA, 90045, USA. 4. HeadsUp Laboratory, Department of Psychology, Loyola Marymount University, 1 LMU Drive Suite 4700, Los Angeles, CA, 90045, USA.
Abstract
INTRODUCTION: The purpose of this study was to compare bone mineral density (BMD) and bone turnover markers between combined oral contraceptive (COC) and non-COC users over 12 months. MATERIALS AND METHODS: COC users (n = 34, age = 19.2 ± 0.5) and non-COC users (n = 28, age = 19.3 ± 0.6) provided serum at baseline, 6 months, and 12 months. C-terminal telopepetides (CTX) and pro-collagen type 1 N-terminal propeptides (P1NP) were determined using ELISA. BMD was measured at the three time points using dual-energy x-ray absorptiometry (DXA). RESULTS: COC users had greater CTX than non-COC users at baseline (18.6 ± 8.2 vs. 13.8 ± 5.3 ng/mL, P = 0.021) and 6 months (20.4 ± 10.3 vs. 14.2 ± 8.5 ng/mL, P = 0.018). Controlling for lean mass, groups were similar in BMD. Over 12 months, non-COC users maintained BMD at the spine, while the COC users declined 2.2% in lateral spine BMD (0.773 ± 0.014 to 0.756 ± 0.014 g/cm2, P = 0.03) and 0.7% in anterior-posterior spine BMD (1.005 ± 0.015 to 0.998 ± 0.015 g/cm2, P = 0.069). Non-COC users increased in BMD of the whole body over 12 months (P < 0.001) while COC users had no change. Women who began COCs within 4 years after menarche had lower BMD at the hip and whole body. Women taking very low dose COCs (20 mcg ethinyl estradiol, EE) significantly declined in CTX, P1NP, and lateral spine BMD in comparison to participants using low dose COCs (30/35 mcg EE). CONCLUSION: College-aged women who did not use COCs increased BMD of the whole body, while COC users had elevated bone turnover, declines in spinal BMD, and lack of bone acquisition of the whole body over 12 months. Young females who initiate COC use early after menarche may experience skeletal detriments.
INTRODUCTION: The purpose of this study was to compare bone mineral density (BMD) and bone turnover markers between combined oral contraceptive (COC) and non-COC users over 12 months. MATERIALS AND METHODS: COC users (n = 34, age = 19.2 ± 0.5) and non-COC users (n = 28, age = 19.3 ± 0.6) provided serum at baseline, 6 months, and 12 months. C-terminal telopepetides (CTX) and pro-collagen type 1 N-terminal propeptides (P1NP) were determined using ELISA. BMD was measured at the three time points using dual-energy x-ray absorptiometry (DXA). RESULTS: COC users had greater CTX than non-COC users at baseline (18.6 ± 8.2 vs. 13.8 ± 5.3 ng/mL, P = 0.021) and 6 months (20.4 ± 10.3 vs. 14.2 ± 8.5 ng/mL, P = 0.018). Controlling for lean mass, groups were similar in BMD. Over 12 months, non-COC users maintained BMD at the spine, while the COC users declined 2.2% in lateral spine BMD (0.773 ± 0.014 to 0.756 ± 0.014 g/cm2, P = 0.03) and 0.7% in anterior-posterior spine BMD (1.005 ± 0.015 to 0.998 ± 0.015 g/cm2, P = 0.069). Non-COC users increased in BMD of the whole body over 12 months (P < 0.001) while COC users had no change. Women who began COCs within 4 years after menarche had lower BMD at the hip and whole body. Women taking very low dose COCs (20 mcg ethinyl estradiol, EE) significantly declined in CTX, P1NP, and lateral spine BMD in comparison to participants using low dose COCs (30/35 mcg EE). CONCLUSION: College-aged women who did not use COCs increased BMD of the whole body, while COC users had elevated bone turnover, declines in spinal BMD, and lack of bone acquisition of the whole body over 12 months. Young females who initiate COC use early after menarche may experience skeletal detriments.
Entities:
Keywords:
CTX; Menarche; P1NP; Peak bone mass; Premenopausal
Authors: Catherine M Gordon; Babette S Zemel; Tishya A L Wren; Mary B Leonard; Laura K Bachrach; Frank Rauch; Vicente Gilsanz; Clifford J Rosen; Karen K Winer Journal: J Pediatr Date: 2016-11-03 Impact factor: 4.406
Authors: Manfred Hartard; Christine Kleinmond; Peter Luppa; Otto Zelger; Kathrin Egger; Michael Wiseman; Ernst Rainer Weissenbacher; Dieter Felsenberg; Reinhold G Erben Journal: Contraception Date: 2006-08-17 Impact factor: 3.375
Authors: C M Weaver; C M Gordon; K F Janz; H J Kalkwarf; J M Lappe; R Lewis; M O'Karma; T C Wallace; B S Zemel Journal: Osteoporos Int Date: 2016-02-08 Impact factor: 4.507
Authors: Kathryn E Ackerman; Vibha Singhal; Charumathi Baskaran; Meghan Slattery; Karen Joanie Campoverde Reyes; Alexander Toth; Kamryn T Eddy; Mary L Bouxsein; Hang Lee; Anne Klibanski; Madhusmita Misra Journal: Br J Sports Med Date: 2018-10-09 Impact factor: 13.800
Authors: Stacie H Fleischer; Annalisa K Freire; Katie Brown; Andrew Creer; Dennis L Eggett; Susan Fullmer Journal: Int J Environ Res Public Health Date: 2022-08-19 Impact factor: 4.614